brr interview Tue, 2 Sep 2014 10:30am - Anteo enters into additional agreement, page-57

gga:

I wanted Biotech's view on this question about the technology...but he's not around or maybe not interested.

With an ex Oracle senior executive, and top scientists on the case, I don't think PSY is unprofessional, it is underfunded. They are entering the most expensive phase, the commercialisation phase and they are very squeezed financially. This affects their negotiating position.

This is where they either get a partner, sell licences to a high profile party or sell the technology to the highest bidder. Annoyingly their SP is nearly double ours.